VYNE Therapeutics (VYNE) 10-Q2024 Q1 Quarterly report

Filed: 9 May 24, 4:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: agency, approach, arm, BD, BETi, captioned, CECL, chain, China, committee, conflict, consent, conveniently, country, Cowen, curtail, detachable, dosage, East, economy, embody, environment, exempt, expressly, fibrotic, fixed, Food, foreseeable, freestanding, fully, gel, guarantee, health, healthy, high, hiring, incident, incorrect, individual, inducement, inflation, ingredient, July, large, larger, mechanism, Menlo, Middle, midpoint, military, mode, notification, ordinary, persistence, pool, predecessor, prevalent, proceed, promulgated, pronounced, randomized, relied, remuneration, repurchase, response, responsibility, responsible, RSU, simplified, skilled, soliciting, Taiwan, thereunder, transparency, travel, Ukraine, uncertainty, unforeseen, unrealized, valid, variety, vehicle, vesting, war, worsening

Removed: account, acne, acquisition, adapalene, advantage, affecting, aging, alleviate, amendment, apply, assigned, attributed, back, bad, Bayer, began, burden, calculated, California, capitalizing, care, carefully, choosing, clinic, combined, commenced, commitment, comprised, conform, constraint, copay, coupon, covenanted, decreased, delivery, demonstrated, deploy, depreciation, derivative, dilution, direct, discovered, dispense, dispose, divested, divestiture, doubtful, Dundee, eligibility, eliminating, embedded, emerging, enhanced, established, evaluate, expectation, expired, Facilitation, feet, forecasted, foreign, governmental, growth, handling, holding, imposition, incorporated, increased, incremental, IND, independent, indirect, infringement, instrument, interested, irrevocable, Israel, issuer, Jumpstart, landscape, launch, leading, lease, leased, lessor, LIBOR, lien, Lincoln, local, lower, maintenance, managed, manner, manufacturing, marketed, Master, matured, minocycline, mix, national, office, oncology, opt, optimally, Park, partnering, payer, payor, penalty, pharmacy, point, portfolio, procure, production, prompt, proposed, protect, protracted, rebate, recast, receipt, receiving, record, reduced, regional, relation, release, released, rent, repayment, requirement, requisite, resell, reserved, retail, revised, School, Scotland, secure, selected, selection, shipping, short, shorter, space, specialty, square, Stabilizing, statutory, sublease, suit, summary, Supplemental, termination, transition, transitioned, transportation, treated, typically, ultimately, University, utilization, vary, volume, whatsoever, wholesaler

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VYNE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of VYNE Therapeutics Inc. (the “Company”), for the quarterly period ended March 31, 2024 as filed with the Securities and Exchange Commission (the “Report”), I, Tyler Zeronda, Chief Financial Officer, Treasurer and principal financial officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 9, 2024	By:	/s/ Tyler Zeronda
		Tyler Zeronda Principal Financial Officer

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the Company.